A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults
NCT ID: NCT05693272
Last Updated: 2024-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
47 participants
INTERVENTIONAL
2023-01-31
2024-06-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The COVAC-1 study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1. The spike protein is the part of the virus that is responsible for attaching to the surface of host cells. COVAC-1 contains a TriAdj adjuvant. An adjuvant is a compound that is added to a vaccine to help the vaccine produce a better immune response. The vaccine is expected to stimulate the body to make antibodies against the S1 protein. The antibodies will recognize the viral spike protein if the body is exposed to the virus and prevent COVID-19 illness. In animal studies, the immune response generated by the COVAC-1 vaccine was able to protect the vaccinated animals against a severe SARS-CoV-2 infection.
The COVAC-005 Study is a Phase I, multi-centre trial of a SARS-CoV-2 vaccine booster. This is a randomized, observer-blinded, and placebo-controlled study to assess the safety and immunogenicity of COVAC-1 booster dose administered once in generally healthy adults 18-65 years of age who have received a minimum of 2 doses of an authorized COVID-19 vaccine at least 4 months prior to Day 0.
The study will follow a dose-escalation design to test the safety and immunogenicity of three dosage levels (10, 25 and 50 µg). In each dose escalation group participants will be randomized in a 3:1 ratio, to receive either the investigational product or a placebo, respectively. Stratification will be according to the Investigational product dose received. Sub-analysis will be completed in two age groups, 18-54 and 55-65 years.
Study participants will be initially randomized to the lowest dose of 10 µg or placebo. After approval by the Sponsor and based on the recommendations from the DSMB following the Day 7 safety analysis, new study participants will be allowed to be randomized in the higher dose escalation group of 25 µg. Approval will also be sought from the Sponsor, based upon the DSMB recommendation, to proceed with the higher dose of 50 µg. Within each dose escalation group of 16 participants (12 active vaccine recipients, and 4 placebo recipients) it is proposed to randomize a first cohort of 4 participants, including at least 3 active vaccine recipients, and pending no holding rule is met after 48 hours, as determined by the post-injection phone call, the remaining 12 participants within that dose escalation group will be randomized.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVAC-01 10µg group
12 healthy adults ≥18 years of age receive the vaccine on Day 0.
COVAC-1
Intramuscular vaccine against SARS-CoV-2
COVAC-01 25µg group
12 healthy adults ≥18 years of age receive the vaccine on Day 0.
COVAC-1
Intramuscular vaccine against SARS-CoV-2
COVAC-01 50µg group
12 healthy adults ≥18 years of age receive the vaccine on Day 0.
COVAC-1
Intramuscular vaccine against SARS-CoV-2
Placebo Control
12 healthy adults ≥18 years of age receive a dose of normal saline (placebo) on Day 0.
Saline Placebo
Intramuscular injection of saline placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVAC-1
Intramuscular vaccine against SARS-CoV-2
Saline Placebo
Intramuscular injection of saline placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Good general health as confirmed by assessments completed no more than 30 days before study D0. Participants with mild to moderate well controlled comorbidities or having a medically stable condition, will be eligible. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization due to worsening during the 3 months prior to enrollment, and according to the judgment of the Investigator, hospitalization during the entire study period is not anticipated.
3. Have received a minimum of 2 doses of an authorized COVID-19 vaccine at least 4 months prior to the investigational booster dose injection. Proof of vaccination can be provided as a digital copy of the vaccination receipt on the participant's device, a screenshot of the receipt on the device, or a printed paper copy.
4. Male participants, and heterosexually active females of child-bearing potential, must practice adequate contraception for 30 days prior to the injection and must agree to continue adequate contraception until 180 days after the injection. Negative pregnancy test will be obtained from female participants of child-bearing potential at screening and at Day 0.
5. Provide a written informed consent for the study prior to performing any study-related procedure. The Investigator or a qualified designee must ensure the appropriate consent is in place.
Exclusion Criteria
2. Clinically significant bleeding disorder (e.g., clotting factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injection or venipuncture.
3. Presence of an autoimmune disease.
4. Receiving systemic steroids in doses exceeding 20mg daily of prednisone or equivalent, for ≥ 14 days within 1 month, or has recently received any other cytotoxic or immunosuppressive drug within 6 months prior to the injection of the study vaccine.
5. Has a known malignancy diagnosed within the past 5 years. Participants with basal cell carcinoma or squamous cell carcinoma of the skin are not excluded.
6. Currently receiving systemic immunomodulatory therapy or received chemotherapy within the last 5 years excluding topical agents.
7. Has received blood products or immunoglobulins (IVIg or IMIg) within 3 months of study entry/baseline serologic evaluation.
8. Currently on anti-tuberculosis therapy.
9. Had SARS-CoV-2 infection within 4 months prior to study Day 0. A potential participant is considered to have COVID-19 infection base on one of the following:
* Positive polymerase chain reaction (PCR) or rapid antigen test.
* Documentation in a medical history report.
* Reported by candidate.
10. Has received any non-COVID-19 authorized vaccines (e.g., influenza) within 2 weeks prior to receiving study dose injection.
11. Has received any experimental SARS-CoV-2 / COVID-19 vaccines Receipt of SARSCoV-2/COVID-19 vaccines that were experimental at the time of administration but are currently authorized, more than 6 months prior to Day 0, will not lead to exclusion.
12. Planning to receive booster doses of any authorized COVID-19 vaccine during the first two months days from study vaccination.
13. Abnormal laboratory test results (hematology, biochemistry, and urinalysis) as compared to the local normal lab ranges. To exclude transient abnormalities, laboratory tests may be repeated once. Abnormal lab test results considered not clinically significant by the Investigator will not be exclusionary.
14. Has a history of any reaction or known sensitivity likely to be exacerbated by any component of the study vaccine.
15. Is currently participating in or has participated in a study of an investigational agent within 6 months prior to the injection of the booster vaccine under study.
16. A female is not eligible to participate if she is pregnant or breast feeding
17. Being a member of the study team, or an immediate family member or household member of a member on the study team.
18. Any condition, which in the opinion of the investigator may deem the participant inappropriate for the study.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Government of Canada
OTHER_GOV
Government of Saskatchewan
OTHER_GOV
University of Saskatchewan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Volker Gerdts
Director & CEO Vaccine and Infectious Disease Organization
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diex Recherche Joliette Inc.
Joliette, Quebec, Canada
Diex Recherche Quebec Inc.
Québec, Quebec, Canada
Diex Recherche Sherbrooke
Sherbrooke, Quebec, Canada
DIEX Recherche Victoriaville
Victoriaville, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Garg R, Liu Q, Van Kessel J, Asavajaru A, Uhlemann EM, Joessel M, Hamonic G, Khatooni Z, Kroeker A, Lew J, Scruten E, Pennington P, Deck W, Prysliak T, Nickol M, Apel F, Courant T, Kelvin AA, Van Kessel A, Collin N, Gerdts V, Koster W, Falzarano D, Racine T, Banerjee A. Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern. Vaccine. 2024 Aug 13;42(20):125980. doi: 10.1016/j.vaccine.2024.05.028. Epub 2024 May 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COVAC-005
Identifier Type: -
Identifier Source: org_study_id